These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10893002)

  • 21. [Response of guinea pigs to vaccination with parainfluenza virus 3].
    Sadir AM; Sardi S; Ruiz ML; Blanco Viera FJ; Bolondi A; Parraud JR; Schudel AA
    Rev Argent Microbiol; 1985; 17(1):15-9. PubMed ID: 2829271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Substantiation of optimum condition of parainfluenza-3 virus cultivation for production of vaccines on the finite cell line].
    Bekhzadpur D; Belousova RV; Ivanov IV
    Voen Med Zh; 2013 Apr; 334(4):27-31. PubMed ID: 24000610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parainfluenza virus type 3 (PIV3)-specific and non-virus-specific delayed type hypersensitivity responses in cotton rats given different PIV3 antigen preparations.
    Ambrose MW; Wyde PR
    Vaccine; 1993; 11(3):336-42. PubMed ID: 8383384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
    Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.
    Power UF; Huss T; Michaud V; Plotnicky-Gilquin H; Bonnefoy JY; Nguyen TN
    J Virol; 2001 Dec; 75(24):12421-30. PubMed ID: 11711632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cotton rat model of human parainfluenza 3 laryngotracheitis: virus growth, pathology, and therapy.
    Ottolini MG; Porter DD; Blanco JC; Prince GA
    J Infect Dis; 2002 Dec; 186(12):1713-7. PubMed ID: 12447755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
    Durbin AP; Karron RA
    Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semi-permissive replication and functional aspects of the immune response in a cotton rat model of human parainfluenza virus type 3 infection.
    Ottolini MG; Porter DD; Hemming VG; Hensen SA; Sami IR; Prince GA
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1739-43. PubMed ID: 8760420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
    Slobod KS; Shenep JL; Luján-Zilbermann J; Allison K; Brown B; Scroggs RA; Portner A; Coleclough C; Hurwitz JL
    Vaccine; 2004 Aug; 22(23-24):3182-6. PubMed ID: 15297072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
    Greenberg DP; Walker RE; Lee MS; Reisinger KS; Ward JI; Yogev R; Blatter MM; Yeh SH; Karron RA; Sangli C; Eubank L; Coelingh KL; Cordova JM; August MJ; Mehta HB; Chen W; Mendelman PM
    J Infect Dis; 2005 Apr; 191(7):1116-22. PubMed ID: 15747247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
    Johnson TR; Teng MN; Collins PL; Graham BS
    J Virol; 2004 Jun; 78(11):6024-32. PubMed ID: 15141000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of immunologic response to intranasal and intramuscular parainfluenza-3 live virus vaccines in beef calves challenged experimentally in the feedlot.
    Woods GT; Crandell RA; Mansfield ME
    Res Commun Chem Pathol Pharmacol; 1975 May; 11(1):117-28. PubMed ID: 168620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia.
    Porter DD; Prince GA; Hemming VG; Porter HG
    J Virol; 1991 Jan; 65(1):103-11. PubMed ID: 1845878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of antibodies and anamnestic response in calves vaccinated with inactivated infectious bovine rhinotracheitis virus and parainfluenza-3 virus vaccines.
    Sweat RL
    J Am Vet Med Assoc; 1983 Apr; 182(8):809-11. PubMed ID: 6303996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune responses of dairy cattle to parainfluenza-3 virus in intranasal infectious bovine rhinotracheitis-parainfluenza-3 virus vaccines.
    Burroughs AL; Morrill JL; Bostwick JL; Ridley RK; Fryer HC
    Can J Comp Med; 1982 Jul; 46(3):264-6. PubMed ID: 6290012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease.
    Piedra PA; Camussi G; Ogra PL
    J Gen Virol; 1989 Feb; 70 ( Pt 2)():325-33. PubMed ID: 2732693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.
    Greer CE; Zhou F; Legg HS; Tang Z; Perri S; Sloan BA; Megede JZ; Uematsu Y; Vajdy M; Polo JM
    Vaccine; 2007 Jan; 25(3):481-9. PubMed ID: 17052811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection from parainfluenza-3 virus and persistence of infectious bovine rhinotracheitis virus in sheep vaccinated with a modified live IBR-PI-3 vaccine.
    Lehmkuhl HD; Cutlip RC
    Can J Comp Med; 1985 Jan; 49(1):58-62. PubMed ID: 2985216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.